Omega Ophthalmics raises $7M Series A to push cataract implant toward FDA

What's the deal? Omega OphthalmicsDealroom has a profile for this one. Try Dealroom →, a medical technology company developing implant technology for cataract surgery, has closed a $7 million Series A led by a group of what it called "strategically aligned ultra-high net worth investors." The company also scheduled its FDA pre-submission meeting to advance its Gemini Refractive Capsule toward US approval.

What's the endgame? The Gemini Refractive Capsule is designed to give a stable, biologically integrated platform for intraocular lens (IOL) implantation while preserving the capsular bag. The approach aims to improve long-term refractive stability, enable future lens exchange, and accommodate next-generation ophthalmic technologies.

Where the money goes: The financing will fund product development, intellectual property, regulatory activities, manufacturing scale-up, and clinical planning as Omega prepares for future FDA studies and commercialisation.

Why now? The pre-submission meeting is an early interaction where Omega can align its regulatory pathway and clinical plans with FDA feedback before starting US clinical studies.

"This financing, together with our upcoming FDA pre-submission meeting, represents a significant step forward as we execute our regulatory strategy," said chief executive officer Rick Ifland.

The signal: At $7 million, the round sits in the 48th percentile for size — a mid-sized raise that reflects the capital-heavy, milestone-driven path medtech startups face. For Omega, the money buys time to clear regulatory hurdles before the technology can reach surgeons and patients.

Read more: Morningstar

Image credit: Generated with Gemini